Sonlicromanol (KH176) is an orally active reactive oxygen species (ROS) modulator for the study in mitochondrial disease[1][2].
Sonlicromanol (KH176, 10 mg/kg, ip, twice daily) has promising, but independent and nonadditive, properties for the pharmacological treatment of CI-deficiency-related mitochondrial diseases[3].
[1]. X Jiang, et al. Mechanism of action and potential applications of selective inhibition of microsomal prostaglandin E synthase-1-mediated PGE 2 biosynthesis by sonlicromanol’s metabolite KH176m. Sci Rep. 2021 Jan 13;11(1):880.
[2]. Zikai Feng, et al. Comparative In Vitro Toxicology of Novel Cytoprotective Short-Chain Naphthoquinones. Pharmaceuticals (Basel). 2020 Aug 7;13(8):184.
[3]. Sanne J C M Frambach, et al. Effects of clofibrate and KH176 on life span and motor function in mitochondrial complex I-deficient mice. Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165727.